An individual from Ontario diagnosed with Stage 4 melanoma expressed frustration over the province’s restrictions on accessing public funding for foreign drug treatments. The patient, Alex Shved, resorted to legal action against Ontario Health Insurance Plan rejections after his cancer had progressed to his lungs and bones. Despite winning the legal battle, he voiced disappointment at the government’s subsequent actions, which seemed to further limit opportunities for patients in similar circumstances.
Shved highlighted that following the court’s ruling that deemed the government’s actions unlawful, the government responded by altering the legislation to justify those same actions. Ontario Health Insurance Plan (OHIP) had declined his oncologist’s proposal for him to undergo tumour-infiltrating lymphocyte therapy in Florida, costing approximately US$600,000. OHIP justified its decision by stating that the therapy was under evaluation for public funding within Ontario.
The refusal letter from the executive officer of Ontario public drug programs emphasized that supporting foreign drug therapies during Ontario’s review process could harm the incentive structure for manufacturers participating in Canada’s drug review system. Despite a Divisional Court judgment that criticized OHIP’s lack of substantial reasoning, OHIP persisted in rejecting Shved’s treatment request. Health Minister Sylvia Jones subsequently announced regulatory amendments ensuring that drugs would only be funded overseas if they were already funded locally but temporarily inaccessible.
Jones asserted that the amendments aimed to shield Ontario patients and taxpayers from inflated costs and secure their access to critical medications typically available only abroad. Additionally, the government is seeking a resolution beneficial to both parties in Shved’s case. Shved, who has explored various treatments since his initial diagnosis in 2020, has been advised by his medical team to consider tumour-infiltrating lymphocyte (TIL) therapy. This treatment involves extracting immune cells from tumours, multiplying them, and reintroducing them into the patient to combat cancer cells. While a form of TIL therapy known as lifileucel received Health Canada approval last year, it is currently under review for potential coverage by provincial drug plans, a process that may extend over several years.
